The high expression of SLC2A1 was associated with reduced drug sensitivity of cancer cells to six drugs (Denileukin Diftitox Ontak, DIGOXIN, Arsenic trioxide, Bendamustine, Bortezomib, and Ixazomib citrate), and with increased drug sensitivity of cancer cells to four drugs (Simvastatin, Irofulven, IPI-145, and Dasatinib). This evidence concerns the gene SLC2A1 and cancer.